Bortezomib in the Treatment of Multiple Myeloma [electronic resource] /
Ghobrial, Irene M.editor.
Richardson, Paul G.editor.
Anderson, Kenneth C.editor.
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Description based upon print version of record.
Bortezomib in the Treatment of Multiple Myeloma; Preface; Contents; Bortezomib ́s Scientific Origins and Its Tortuous Path to the Clinic; Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics; Bortezomib and Osteoclasts and Osteoblasts; Bortezomib in the Upfront Treatment of Multiple Myeloma; The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma; Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma; Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management
Bortezomib in Mantle Cell LymphomaBortezomib in Waldenstrom ́s Macroglobulinemia; Bortezomib in Systemic Light-Chain Amyloidosis; Second-Generation Proteasome Inhibitors; Index
Includes bibliographical references and index.
Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Oncology  .
Cancer research.
Pharmacology.
Apoptosis.
Oncology.
Cancer Research.
Pharmacology/Toxicology.
Apoptosis.